RP2 Injection
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-Risk Oral Precancerous Disease
Conditions
High-Risk Oral Precancerous Disease
Trial Timeline
Jan 1, 2025 → Jan 1, 2029
NCT ID
NCT06623110About RP2 Injection
RP2 Injection is a phase 2 stage product being developed by Replimune for High-Risk Oral Precancerous Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06623110. Target conditions include High-Risk Oral Precancerous Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06623110 | Phase 2 | Recruiting |
Competing Products
13 competing products in High-Risk Oral Precancerous Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone | Amgen | Phase 2 | 51 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone | Gilead Sciences | Phase 3 | 76 |
| Darolutamide + ADT | Bayer | Phase 2 | 49 |
| Esmolol | Baxter | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells) | ImmunityBio | Phase 2 | 49 |
| N-803 + ETBX-071 + M-CENK | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | PDS Biotechnology | Phase 1 | 25 |
Other Products from Replimune
Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapyPhase 3
69
RP2 + Ipilimumab + NivolumabPhase 2/3
57
RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 MonotherapyPhase 2
44
RP2 + Pegfilgrastim + FilgrastimPhase 2
44
Vusolimogene Oderparepvec (VO) + PembrolizumabPhase 2
44